Emergent BioSolutions, Inc. (NYSE:EBS)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the development, manufacture and commercialization of immunobiotics. The Company operates in two business segments: biodefense and commercial.

Results 1 - 20 of 47 : 1 2 3 Next »

Recs

0
Member Avatar NathanHamilton82 (< 20) Submitted: 3/25/2014 5:01:38 PM : Outperform Start Price: $25.51 EBS Score: -19.17

Emergent BioSolutions has a mononpoly on anthrax vaccines supplied to the government under multi-year sole source contracts. The company is capacity constrained, and with the US governments $100m investment in expanding capacity, Emergent is on track to triple production through 2017. 100%+ upside!

Recs

0
Member Avatar TerryHoodSr (59.71) Submitted: 7/21/2013 1:25:27 AM : Outperform Start Price: $17.85 EBS Score: +7.11

growth

Recs

0
Member Avatar RedDoor9 (24.13) Submitted: 9/2/2012 9:02:49 PM : Outperform Start Price: $14.70 EBS Score: +10.17

Rock solid business model and the only provider of anthrax treatments for the US government. Stock has been punished despite new contract with government. Nice value play in turbulent times.

Recs

0
Member Avatar RallyCry (< 20) Submitted: 3/19/2012 3:23:06 PM : Outperform Start Price: $15.66 EBS Score: +0.91

A PEG of .36 says it all. 45% earnings growth in 2013 trading at 16.31 times 2013 projections. Reasonable levels of cash to long term debt of around 3 x. Top pick for 2012.

Recs

2
Member Avatar EnigmaDude (93.12) Submitted: 10/3/2011 4:51:08 PM : Outperform Start Price: $16.89 EBS Score: -52.05

Emergent BioSolutions receives award to supply 44.75 mln doses of BioThrax to U.S. Government over 5 Years for a total value of up to $1.25 bln

Recs

0
Member Avatar TrojanFan (26.04) Submitted: 7/7/2011 4:13:41 PM : Outperform Start Price: $21.89 EBS Score: -47.15

Recent approval of Biothraxx by Singapore HSA is a promising development as the company tries to expand its marketing reach into other places such as Brunei.

I'm a little nervous about the impact of the debt ceiling debate and the potential for delayed or reduced purchases by the US govt, but given the homeland security angle that should offer them some protection.

I'm looking for good earnings for last quarter because their press releases indicate that they shipped a LOT of product this quarter.

Recs

0
Member Avatar NicolasDarvas (50.25) Submitted: 1/6/2011 6:56:16 PM : Outperform Start Price: $23.67 EBS Score: -62.11

Test, 2011.

Recs

0
Member Avatar williamscaps (< 20) Submitted: 9/27/2010 12:55:42 PM : Underperform Start Price: $18.80 EBS Score: +49.90

18.78

Recs

2
Member Avatar whirlyfish (< 20) Submitted: 2/17/2010 11:23:38 AM : Outperform Start Price: $14.79 EBS Score: -30.79

TB and Chlamydia vaccines. As well as upcoming antgrax demand.

Recs

0
Member Avatar blackmonday2007 (< 20) Submitted: 9/15/2009 11:52:59 AM : Outperform Start Price: $19.59 EBS Score: -76.12

MIKE TURNER PICK

Recs

0
Member Avatar cayamax (< 20) Submitted: 9/11/2009 11:09:20 AM : Outperform Start Price: $19.27 EBS Score: -74.78

Sadly, bioterrorism and biowarfare will be a threat for quite awhile.

Recs

0
Member Avatar dantefromsomm (< 20) Submitted: 9/3/2009 11:50:30 PM : Outperform Start Price: $17.54 EBS Score: -71.53

Very high insider ownership with alot of potential for blow ups with product develope ments.Same basic formula i like.Increasing balance sheets, reasonably low p/e,good insider ownership,low debt.

Recs

0
Member Avatar Ulenspiegel101 (< 20) Submitted: 6/2/2009 3:07:11 PM : Outperform Start Price: $11.89 EBS Score: -24.29

proven innovator

Recs

0
Member Avatar Tyrone85 (95.09) Submitted: 2/19/2009 9:57:09 PM : Outperform Start Price: $21.02 EBS Score: -158.34

after/ 1st q of 2009

Recs

0
Member Avatar fivehaus (79.87) Submitted: 2/19/2009 9:56:35 AM : Outperform Start Price: $22.59 EBS Score: -155.33

Daily, weekly. monthly trends are up. Increasing sales, increasing earnings. a good sales base with the U.S. Military.

Recs

0
Member Avatar cjstock02 (< 20) Submitted: 1/28/2009 2:59:20 PM : Underperform Start Price: $21.11 EBS Score: +126.23

We developed a gap down after a long run up. That looks very bearish on the chart.

Recs

1
Member Avatar sprucemoose2 (26.02) Submitted: 1/5/2009 2:27:31 PM : Outperform Start Price: $26.07 EBS Score: -133.00

has a constant revenue stream from the good ole US of A and sticks to its 50 day MA very well

Recs

1
Member Avatar viasyncro (< 20) Submitted: 12/20/2008 12:34:07 PM : Outperform Start Price: $25.97 EBS Score: -143.09

Niche company with growing market share

Recs

0
Member Avatar MalibuGuru (81.69) Submitted: 12/9/2008 5:08:54 PM : Outperform Start Price: $24.40 EBS Score: -134.96

Emergent BioSolutions maintains a large economic moat through it's Biothrax vaccine. Two of it's vaccines in late stage development, a typhoid vaccine candidate and a hepatitis B therapeutic vaccine candidate, uniquely positions EBS to take advantage of the expected huge growth of demand in LDC and MDC.

Recs

0
Member Avatar DNAdivaSTL (57.87) Submitted: 12/2/2008 4:18:53 PM : Outperform Start Price: $13.48 EBS Score: +6.67

When your biggest customer is Big Brother, growth is inevitable....

Results 1 - 20 of 47 : 1 2 3 Next »

Featured Broker Partners


Advertisement